Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Kura Oncology, Inc. (NASDAQ: KURA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARDX, TNDM and VIAV are among after hour movers [Seeking Alpha]
Kura Oncology Reports First Quarter 2024 Financial Results [Yahoo! Finance]